Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Analysis of EGFR gene mutation in patients with Non-Small cell lung cancer in Hue Central hospital

View through CrossRef
Objective: To analyze the EGFR mutation index on the cancer blocs of the patients with non - small cell lung cancer (NSCLC) at the Department of Pathology - Hue Central Hospital. Subjects and methods: A prospective, cross-sectional descriptive study of 227 patients with advanced, metastatic non - small cell lung cancer who were mutated in the EGFR gene. The study were carried out on the cancer parrafin blocs stored in Pathology Department, Hue Central Hospital. Results: Mean age 58.29 ± 9.36 years old, male/female ratio 1.58. Histopathology is mainly adenocarcinoma: 96%, squamous epithelium: 0.9%, large cell: 3.1%. EGFR mutation rate positive 38.3%, negative: 61.7%. The rate of positive EGFR mutations in women: (53.4%) is higher than in men: (28.8%). The rate of positive EGFR mutations in the smoking group: (24.4%), insignificant smoking: (32.8%), the non - smoking group (56.6%). The cases of patients carrying mutations in EGFR gene have 50.6% of LREA deletion mutations in exon 19; 40.23% are L858R substitution mutations in exon 21; 3.45% are G719X mutations and 2.3% are G719S mutations in exon 18; 1.14% are Q787 mutations in exon 20; 1.14% are double mutations S768I + V769L in exon 20 and T790M + L858R in exons 20 and 21. Conclusion: The rate of EGFR gene mutation in NSCLC patients was 38.3%, higher in women than in men and especially high in non - smokers or non - smokers, the difference was statistically significant with p. < 0.05. The most common TKI - sensitive mutations include deletion mutations in exon 19 and substitution mutations in exon 21 (accounting for more than 90%), a percentage less than 5% are mutations.
Title: Analysis of EGFR gene mutation in patients with Non-Small cell lung cancer in Hue Central hospital
Description:
Objective: To analyze the EGFR mutation index on the cancer blocs of the patients with non - small cell lung cancer (NSCLC) at the Department of Pathology - Hue Central Hospital.
Subjects and methods: A prospective, cross-sectional descriptive study of 227 patients with advanced, metastatic non - small cell lung cancer who were mutated in the EGFR gene.
The study were carried out on the cancer parrafin blocs stored in Pathology Department, Hue Central Hospital.
Results: Mean age 58.
29 ± 9.
36 years old, male/female ratio 1.
58.
Histopathology is mainly adenocarcinoma: 96%, squamous epithelium: 0.
9%, large cell: 3.
1%.
EGFR mutation rate positive 38.
3%, negative: 61.
7%.
The rate of positive EGFR mutations in women: (53.
4%) is higher than in men: (28.
8%).
The rate of positive EGFR mutations in the smoking group: (24.
4%), insignificant smoking: (32.
8%), the non - smoking group (56.
6%).
The cases of patients carrying mutations in EGFR gene have 50.
6% of LREA deletion mutations in exon 19; 40.
23% are L858R substitution mutations in exon 21; 3.
45% are G719X mutations and 2.
3% are G719S mutations in exon 18; 1.
14% are Q787 mutations in exon 20; 1.
14% are double mutations S768I + V769L in exon 20 and T790M + L858R in exons 20 and 21.
Conclusion: The rate of EGFR gene mutation in NSCLC patients was 38.
3%, higher in women than in men and especially high in non - smokers or non - smokers, the difference was statistically significant with p.
< 0.
05.
The most common TKI - sensitive mutations include deletion mutations in exon 19 and substitution mutations in exon 21 (accounting for more than 90%), a percentage less than 5% are mutations.

Related Results

Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract Purpose: Advanced stage lung adenocarcinoma patients with activating EGFR mutation have better survival result after EGFR tyrosine kinase inhibitor develope...
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract BACKGROUND Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance i...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract Introduction  Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract Introduction Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...

Back to Top